# Comparison of multiple doses of corticosteroids in Kawasaki disease: a Bayesian network analysis

## TL;DR

This study compares different corticosteroid doses for Kawasaki disease, finding that adding high-dose steroids to IVIG helps control symptoms, while low-dose steroids help prevent heart complications.

## Contribution

The study introduces a Bayesian network analysis to compare corticosteroid dosing strategies in Kawasaki disease for both acute and long-term outcomes.

## Key findings

- IVIG-plus-HDMP is most effective for acute symptom control in high-risk or IVIG-resistant KD.
- IVIG-plus-LDP is best for preventing coronary artery dilation in general KD cases.
- Corticosteroid side effects were mild and reversible across all regimens.

## Abstract

Kawasaki disease (KD) is a leading cause of acquired heart disease in children, with coronary artery lesion (CAL) as a major complication. Although intravenous immunoglobulin (IVIG) remains the cornerstone of therapy, corticosteroids continue to play an important role in the management of IVIG-resistant, high-risk, or severe Kawasaki disease. Nevertheless, the optimal dosing strategies and differential therapeutic effects of corticosteroids in children with distinct clinical subtypes of KD remain poorly understood, particularly in those at highest risk.

We conducted a Bayesian network meta-analysis of five regimens: intravenous immunoglobulin alone (IVIG-alone), medium-dose methylprednisolone alone (MDMP-alone), high-dose methylprednisolone alone (HDMP-alone), IVIG-plus-low-dose methylprednisolone (IVIG-plus-LDP), and IVIG-plus-HDMP. Data from randomized controlled trials (RCTs) through December 2024 were included.

IVIG-plus-HDMP ranked highest for preventing treatment resistance and reducing fever in initial and refractory KD [Surface Under the Cumulative Ranking Curve (SUCRA) 0.79]. IVIG-plus-LDP had the highest probability of reducing coronary artery dilation (CAD) incidence (SUCRA 0.89). Corticosteroid-related side effects (e.g., bradycardia, hypertension) were mild, transient, and reversible across all regimens, with no severe adverse events reported.

IVIG-plus-HDMP is the most effective therapy for acute symptom control in KD, particularly in high-risk or IVIG-resistant cases, while IVIG-plus-LDP appears superior for long-term prevention of coronary complications in the general KD population. Treatment selection should be individualized based on patient risk profile and treatment priorities, balancing rapid symptom management against long-term coronary outcomes.

https://www.crd.york.ac.uk/prospero/, identifier CRD42022339937.